intraosseous spindle cell rhabdomyosarcoma with TFCP2/NCOA2 rearrangements

Summary

intraosseous spindle cell rhabdomyosarcoma with TFCP2/NCOA2 rearrangements (MONDO:0100055) is a disease. A subtype of spindle cell rhabdomyosarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	intraosseous spindle cell rhabdomyosarcoma with TFCP2/NCOA2 rearrangements
Mondo ID	MONDO:0100055
NCIT	C178236
UMLS	C5554888
MedGen	1791329
GARD	0026027
Is cancer (heuristic)	no

Also known as: intraosseous rhabdomyosarcoma defined by FUS-TFCP2 fusion · intraosseous rhabdomyosarcoma with FUS-TFCP2 fusion

Disease family

This is a subtype of spindle cell rhabdomyosarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › sarcoma › spindle cell sarcoma › spindle cell rhabdomyosarcoma › intraosseous spindle cell rhabdomyosarcoma with TFCP2/NCOA2 rearrangements

Related subtypes (2): congenital/infantile spindle cell rhabdomyosarcoma with VGLL2/NCOA2/CITED2 rearrangements, childhood spindle cell rhabdomyosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.